You are leaving Medscape Education
Cancel Continue
Log in to save activities Your saved activities will show here so that you can easily access them whenever you're ready. Log in here CME & Education Log in to keep track of your credits.
 

 

CME / ABIM MOC / CE

Answers From the Experts: Pre-Exposure Prophylaxis in Primary Care -- An Interview Series

  • Authors: Kara S. McGee, DMS, MSPH, PA-C, AAHIVS
  • CME / ABIM MOC / CE Released: 11/17/2022
  • Valid for credit through: 11/17/2023
Start Activity

  • Credits Available

    Physicians - maximum of 0.50 AMA PRA Category 1 Credit(s)™

    ABIM Diplomates - maximum of 0.50 ABIM MOC points

    Nurses - 0.50 ANCC Contact Hour(s) (0.25 contact hours are in the area of pharmacology)

    Pharmacists - 0.50 Knowledge-based ACPE (0.050 CEUs)

    Physician Assistant - 0.50 AAPA hour(s) of Category I credit

    IPCE: 0.50 Interprofessional Continuing Education (IPCE) credit

    You Are Eligible For

    • Letter of Completion
    • ABIM MOC points

Target Audience and Goal Statement

This activity is intended for primary care physicians, infectious disease/HIV specialists, nurses, physician assistants, and advanced practice nurses.

The goal of this activity is for learners to be better able to assess whether a patient might benefit from pre-exposure prophylaxis (PrEP) and develop a tailored strategy for implementing PrEP in the primary care setting.

Upon completion of this activity, participants will:

  • Have increased knowledge regarding the
    • Recommended assessment prior to initiating PrEP
  • Have greater competence related to
    • Development of tailored patient care strategies for initiating PrEP
  • Demonstrate greater confidence in their ability to
    • Develop an integrated interprofessional model to offer PrEP services in primary care


Disclosures

Medscape, LLC requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

All relevant financial relationships for anyone with the ability to control the content of this educational activity are listed below and have been mitigated. Others involved in the planning of this activity have no relevant financial relationships.

Disclosures for additional planners can be found here.


Faculty

  • Kara S. McGee, DMS, MSPH, PA-C, AAHIVS

    Associate Clinical Professor
    Duke University School of Nursing
    Durham, North Carolina

    Disclosures

    Kara S. McGee, DMS, MSPH, PA-C, AAHIVS, has no relevant financial relationships.

Editors

  • Ashley Stumvoll, MRes

    Associate Medical Writer, Medscape Education, LLC

    Disclosures

    Ashley Stumvoll, MRes, has no relevant financial relationships.

  • Maria B. Uravich, BSc, ELS

    Senior Medical Education Director, Medscape Education, LLC

    Disclosures

    Maria B. Uravich, BSc, ELS, has no relevant financial relationships. 

Compliance Reviewer/Nurse Planner

  • Leigh Schmidt, MSN, RN, CNE, CHCP

    Associate Director, Accreditation and Compliance, Medscape, LLC

    Disclosures

    Leigh Schmidt, MSN, RN, CNE, CHCP, has no relevant financial relationships.


Accreditation Statements



In support of improving patient care, Medscape, LLC is jointly accredited with commendation by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

This activity was planned by and for the healthcare team, and learners will receive 0.50 Interprofessional Continuing Education (IPCE) credit for learning and change.

    For Physicians

  • Medscape, LLC designates this enduring material for a maximum of 0.50 AMA PRA Category 1 Credit(s). Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.50 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. Aggregate participant data will be shared with commercial supporters of this activity.

    Contact This Provider

    For Nurses

  • Awarded 0.50 contact hour(s) of nursing continuing professional development for RNs and APNs; 0.25 contact hours are in the area of pharmacology.

    Contact This Provider

    For Pharmacists

  • Medscape designates this continuing education activity for 0.50 contact hour(s) (0.050 CEUs) (Universal Activity Number: JA0007105-0000-22-401-H02-P).

    Contact This Provider

  • For Physician Assistants

    Medscape, LLC has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 0.50 AAPA Category 1 CME credits. Approval is valid until 11/17/2023. PAs should only claim credit commensurate with the extent of their participation.

For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]


Instructions for Participation and Credit

There are no fees for participating in or receiving credit for this online educational activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

This activity is designed to be completed within the time designated on the title page; physicians should claim only those credits that reflect the time actually spent in the activity. To successfully earn credit, participants must complete the activity online during the valid credit period that is noted on the title page. To receive AMA PRA Category 1 Credit™, you must receive a minimum score of 70% on the post-test.

Follow these steps to earn CME/CE credit*:

  1. Read about the target audience, learning objectives, and author disclosures.
  2. Study the educational content online or print it out.
  3. Online, choose the best answer to each test question. To receive a certificate, you must receive a passing score as designated at the top of the test. We encourage you to complete the Activity Evaluation to provide feedback for future programming.

You may now view or print the certificate from your CME/CE Tracker. You may print the certificate, but you cannot alter it. Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period, you can print out the tally as well as the certificates from the CME/CE Tracker.

*The credit that you receive is based on your user profile.

CME / ABIM MOC / CE

Answers From the Experts: Pre-Exposure Prophylaxis in Primary Care -- An Interview Series

Authors: Kara S. McGee, DMS, MSPH, PA-C, AAHIVSFaculty and Disclosures

CME / ABIM MOC / CE Released: 11/17/2022

Valid for credit through: 11/17/2023

processing....

References

  1. World Health Organization. Consolidated HIV strategic information guidelines driving impact through programme monitoring and management. Accessed July 7, 2022. https://apps.who.int/iris/handle/10665/331697
  2. US Public Health Service. Preexposure prophylaxis for the prevention of HIV infection in the United States -- 2021 update: A clinical practice guideline. 2021. July 7, 2022. https://www.cdc.gov/hiv/pdf/risk/prep/cdc-hiv-prep-guidelines-2021.pdf
  3. Fonner VA, et al. Effectiveness and safety of oral HIV preexposure prophylaxis for all populations. AIDS Lond Engl. 2016;30:1973-1983.
  4. Centers for Disease Control and Prevention (CDC). Taking a sexual history. Accessed July 7, 2022. https://www.cdc.gov/hiv/clinicians/transforming-health/health-care-providers/sexual-history.html
  5. Zanoni BC, et al. The adolescent and young adult HIV cascade of care in the United States: exaggerated health disparities. AIDS Patient Care STDS. 2014;28:128-135.
  6. Teitelman AM, et al. Beliefs associated with intention to use PrEP among cisgender U.S. women at elevated HIV risk. Arch Sex Behav. 2020;49:2213-2221.
  7. Leech AA, et al. Healthcare practitioner experiences and willingness to prescribe pre-exposure prophylaxis in the US. PLoS One. 2020;15:e0238375.
  8. Storholm ED, et al. Primary care providers' knowledge, attitudes, and beliefs about HIV pre-exposure prophylaxis (PrEP): informing network-based interventions. AIDS Educ Prev. 2021;33:325-344.
  9. Ogunbajo A, et al. Multilevel barriers to HIV PrEP uptake and adherence among Black and Hispanic/Latinx transgender women in southern California. AIDS Behav. 2021;25:2301-2315.
  10. Kimball D, et al. Medical mistrust and the PrEP cascade among Latino sexual minority men. AIDS Behav. 2020;24:3456-3461.
  11. Cahill S, et al. Stigma, medical mistrust, and perceived racism may affect PrEP awareness and uptake in black compared to white gay and bisexual men in Jackson, Mississippi and Boston, Massachusetts. AIDS Care. 2017;29:1351-1358.
  12. Tekeste M, et al. Differences in medical mistrust between Black and White women: implications for patient-provider communication about PrEP. AIDS Behav. 2019;23:1737-1748.
  13. Centers for Disease Control and Prevention (CDC). HIV surveillance report: diagnoses of HIV infection in the United States and dependent areas 2020. 2022. Accessed June 15, 2022. https://www.cdc.gov/hiv/library/reports/hiv-surveillance/vol-33/index.html
  14. Krakower D, et al. HIV providers' perceived barriers and facilitators to implementing pre-exposure prophylaxis in care settings: a qualitative study. AIDS Behav. 2014;18:1712-1721.
  15. Auerbach JD, et al. Beyond "getting drugs into bodies": social science perspectives on pre-exposure prophylaxis for HIV. J Int AIDS Soc. 2015;18:19983.
  16. Sayood S, et al. Low knowledge of HIV PrEP within a Midwestern US cohort of persons who inject drugs. Open Forum Infect Dis. 2021;9:ofab541.
  17. Petroll AE, et al. PrEP awareness, familiarity, comfort, and prescribing experience among US primary care providers and HIV specialists. AIDS Behav. 2017;21:1256-1267.
  18. Mansergh G, et al. Preference for using a variety of future HIV pre-exposure prophylaxis products among men who have sex with men in three US cities. J Int AIDS Soc. 2021;24:e25664.
  19. Elopre L, et al. PrEP service delivery preferences of Black cis-gender women living in the Southern United States. AIDS Behav. 2022;26:3469-3479.
  20. Evans KN, et al. The potential of telecommunication technology to address racial/ethnic disparities in HIV PrEP awareness, uptake, adherence, and persistence in care: a review. AIDS Behav. 2022;26:3878-3888.
  21. Giovenco D, et al. Adapting technology-based HIV prevention and care interventions for youth: lessons learned across five U.S. Adolescent Trials Network studies. mHealth. 2021;7:21.
  22. Mayer KH, et al. Emtricitabine and tenofovir alafenamide vs emtricitabine and tenofovir disoproxil fumarate for HIV pre-exposure prophylaxis (DISCOVER): primary results from a randomised, double-blind, multicentre, active-controlled, phase 3, non-inferiority trial. Lancet. 2020;396:239-254.
  23. Cabotegravir extended-release injectable suspension with rilpivirine extended-release injectable suspension [prescribing information]. Approved January 2021. Revised January 2021.
  24. Landovitz RJ, et al. Cabotegravir for HIV prevention in cisgender men and transgender women. N Engl J Med. 2021;385:595-608.
  25. Parsons JT, et al. Familiarity with and preferences for oral and long-acting injectable HIV pre-exposure prophylaxis (PrEP) in a national sample of gay and bisexual men in the U.S. AIDS Behav. 2016;20:1390-1399.
  26. Irie WC, et al. Preferences for HIV preexposure prophylaxis products among Black women in the U.S. AIDS Behav. 2022;26:2212-2223.
  27. Fields EL, et al. Young black MSM's exposures to and discussions about PrEP while navigating geosocial networking apps. J LGBT Youth. 2019;18:23-39.
  28. Engelman KD, et al. Long-acting cabotegravir for HIV/AIDS prophylaxis. Biochemistry. 2021;60:1731-1740.
  29. Henkhaus ME, et al. Barriers and facilitators to use of a mobile HIV care model to re-engage and retain out-of-care people living with HIV in Atlanta, Georgia. PLoS One. 2021;16:e0247328.
  30. Patel D, et al. Estimating gains in HIV testing by expanding HIV screening at routine checkups. Am J Public Health. 2021;111:1530-1533.
  31. Rowan SE, et al. Same-day prescribing of daily oral pre-exposure prophylaxis for HIV prevention. Lancet HIV. 2020;8:e114-e120.
  32. National Clinician Consultation Center. Translating science into care: PrEP: pre-exposure prophylaxis. Accessed July 7, 2022. https://nccc.ucsf.edu/clinician-consultation/prep-pre-exposure-prophylaxis/
  33. Centers for Disease Control and Prevention (CDC). HIV risk estimator tool. Accessed July 7, 2022. https://hivrisk.cdc.gov/risk-estimator-tool/#-sb
« Return to: Answers From the Experts: Pre-Exposure Prophylaxis in Primary Care -- An Interview Series